# A Single Escalating Dose Study Of Ertugliflozin (PF-04971729, MK-8835) Under Fed and Fasted Conditons In Healthy Volunteers (MK-8835-036)

> **NCT00989079** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 24 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Ertugliflozin
- **DRUG:** Placebo to Ertugliflozin

## Key facts

- **NCT ID:** NCT00989079
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10-16
- **Primary completion:** 2009-12-11
- **Final completion:** 2009-12-11
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2020-05-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00989079

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00989079, "A Single Escalating Dose Study Of Ertugliflozin (PF-04971729, MK-8835) Under Fed and Fasted Conditons In Healthy Volunteers (MK-8835-036)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00989079. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*